Convalescent Plasma

Treatment with convalescent plasma reduced 28-day mortality among adults undergoing mechanical ventilation for COVID-19-induced acute respiratory distress syndrome, according to results published in The New England Journal of Medicine.

Compared with placebo, convalescent plasma with neutralizing

Convalescent plasma, when administered within 9 days of symptom onset in patients with COVID-19, may reduce the risk for hospitalization, according to data published in The New England Journal of Medicine.

Convalescent plasma with high neutralizing antibodies produced a strong and rapid viral clearance when administered to patients hospitalized with COVID-19, according to recent data.

Convalescent plasma appeared safe and effective for the treatment of COVID-19 among patients with primary antibody deficiency, according to a study published in Journal of Clinical Immunology.

Results from the CONTAIN COVID-19 trial showed that convalescent plasma did not meet prespecified efficacy endpoints in patients hospitalized with COVID-19.

Convalescent plasma failed to reduce progression to severe respiratory failure or death within 30 days in patients with moderate to severe COVID-19 pneumonia, according to a new study published in JAMA Network Open.

A recent study showed no significant difference in COVID-19 disease severity, progression, mortality or hospitalization between high-risk patients who received convalescent plasma compared with those who received placebo.

COVID-19 convalescent plasma administered within 7 days of symptom onset did not appear to prevent disease progression among high-risk outpatients with COVID-19, according to study results published in The New England Journal of Medicine.

Convalescent plasma treatment appeared associated with a reduction in 30-day mortality among patients with hematologic malignancies hospitalized for COVID-19, according to study results published in JAMA Oncology.